Your browser doesn't support javascript.
loading
Oncolytic virotherapy for human malignant mesothelioma: recent advances.
Boisgerault, Nicolas; Achard, Carole; Delaunay, Tiphaine; Cellerin, Laurent; Tangy, Frédéric; Grégoire, Marc; Fonteneau, Jean-François.
Afiliação
  • Boisgerault N; INSERM, UMR892, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; CNRS, UMR6299, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; University of Nantes, Paris, CNRS UMR-3569, France.
  • Achard C; INSERM, UMR892, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; CNRS, UMR6299, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; University of Nantes, Paris, CNRS UMR-3569, France.
  • Delaunay T; INSERM, UMR892, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; CNRS, UMR6299, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; University of Nantes, Paris, CNRS UMR-3569, France.
  • Cellerin L; Nantes CHU Hospital, Department of Thoracic and Digestive Oncology, Institut Pasteur, Paris, CNRS UMR-3569, France.
  • Tangy F; Viral Genomics and Vaccination Unit, Institut Pasteur, Paris, CNRS UMR-3569, France.
  • Grégoire M; INSERM, UMR892, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; CNRS, UMR6299, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; University of Nantes, Paris, CNRS UMR-3569, France.
  • Fonteneau JF; INSERM, UMR892, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; CNRS, UMR6299, Health Research Institute of the University of Nantes, Paris, CNRS UMR-3569, France; University of Nantes, Paris, CNRS UMR-3569, France.
Oncolytic Virother ; 4: 133-40, 2015.
Article em En | MEDLINE | ID: mdl-27512676
ABSTRACT
Cancer virotherapy is an attractive alternative to conventional treatments because it offers a wide range of antitumor effects due to 1) the diversity of the oncolytic viruses that are now available and 2) their multifaceted activities against both tumor cells and tumor vessels, in addition to their ability to induce antitumor immune responses. In this review, we summarize preclinical and clinical data regarding the targeting of malignant mesothelioma (MM) by oncolytic viruses. We also discuss the potential of other oncolytic viruses that have already shown antitumor effects against several malignancies in advanced clinical trials but are yet to be tested against MM cells. Finally, we review how the activation of the immune system and combinations with other types of anticancer treatments could support the development of oncolytic virotherapy for the treatment of MM.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncolytic Virother Ano de publicação: 2015 Tipo de documento: Article País de afiliação: França
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncolytic Virother Ano de publicação: 2015 Tipo de documento: Article País de afiliação: França